The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study on TIL for the Treatment of Advanced Hepatobiliary-Pancreatic Cancers
Official Title: A Clinical Study on TIL for the Treatment of Advanced Hepatobiliary-Pancreatic Cancers
Study ID: NCT05098197
Brief Summary: This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced hepatobiliary-pancreatic cancers. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Shanghai Tenth People's Hospital, Shanghai, Shanghai, China